Tuberculosis and Antimicrobial Resistance
We explore how HIV drives TB, examine the emergence of drug resistance, and investigate links with co-infections such as sepsis.
Our One Health approaches and global partnerships ensure impact across a range of settings, from remote clinics to urban health systems.
By combining microbiology, health economics, and social science, we co-develop practical, equitable solutions that improve outcomes and influence policy.
LSTM’s work supports the WHO End TB Strategy and global action on AMR through innovation and real-world delivery.
Centres of Excellence
Our specialist Centres, Units and Institutes lead research into tuberculosis and anti-microbial Resistance. By uniting clinical, scientific and operational expertise, they drive innovation in diagnostics, treatment and disease elimination, working with global partners to reduce burden and improve health outcomes.
Meet the team tackling tuberculosis and antimicrobial resistance through world-class research and practical solutions.
Professor Adam Roberts
Professor Roberts examines how antimicrobial resistance spreads and how to stop it, combining drug discovery, molecular microbiology, and public engagement to develop new treatments and limit resistance in bacteria
Dr Vibol Iem
Dr. Vibol Iem is a Postdoctoral Research Associate, contributing to the Start4All and Leaving no on-one behind: Gendered pathways to health of TB consortia.
Dr Shevin Jacob
Dr Jacob is a Reader in Sepsis Research whose work focuses on improving the management of severe infections in low-resource settings, particularly through sepsis research and capacity building in Africa.
Featured projects
Tiny Targets: Eliminating sleeping sickness through vector control
Tiny Targets is an innovative vector control initiative led by LSTM and partners to reduce the spread of sleeping sickness.
Anti-Wolbachia Consortium (A·WOL)
The Anti-Wolbachia Consortium (A·WOL), led by LSTM, is pioneering a novel approach to treating filarial diseases by targeting Wolbachia bacteria.
Hybridisation in UroGenital Schistosomiasis (HUGS)
The Hybridisation in UroGenital Schistosomiasis (HUGS) project is an international research collaboration focused on understanding the impact of parasite hybridisation on disease control.
